Fudan University: Colorectal Neoplasms trials

The registry lists 118 Colorectal Neoplasms studies with Fudan University as lead sponsor. 60 are open to participants now and 0 have results posted.

Phase 1 4Phase 2 56Phase 3 14Phase 4 7No phase 39(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal CancerRecruitingNCT07884188Phase 2
• Savolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type Metastatic Colorectal CancerNot yet recruitingNCT07683403Phase 1/2
• AI-empowered Nudge to Improve Colonoscopy Uptake (AINC)Not yet recruitingNCT07612436Not applicable
• A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant ChemotherapyRecruitingNCT07604909Phase 2
• Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal CancerRecruitingNCT07562711Phase 2
• Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal CancerRecruitingNCT07562659Phase 2
• Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal CancerRecruitingNCT07562503Phase 2
• A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal CancerRecruitingNCT07562490Phase 2
• Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal CancerNot yet recruitingNCT07403877Phase 2
• Comparative Study on the Short- and Long-term Efficacy of Q-ISR, Traditional Sub-ISR, and t-ISRRecruitingNCT07371273Phase 2
• Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)Not yet recruitingNCT07362836Phase 3
• Using ctDNA Methylation to Monitor Metastatic Colorectal Cancer Treatment (PROMET)RecruitingNCT07283575
• Effect of OFA, OSA Versus Opioid-based Anesthesia on NETs and Cancer Cell Malignancy After Colorectal Cancer SurgeryRecruitingNCT07264556Not applicable
• AI-assisted Integrated Care to Promote Colonoscopy UptakeNot yet recruitingNCT07261059Not applicable
• Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal CancerRecruitingNCT07154316Phase 2
• Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal CancerNot yet recruitingNCT07025850Phase 1/2
• Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRCRecruitingNCT07003022Phase 2
• Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer PatientsNot yet recruitingNCT06999252Phase 2
• Effect of Surgical Margin Width on Recurrence and Survival in Patients With Hepatic Oligometastasis of Colorectal CancerRecruitingNCT06934018Not applicable
• A Prospective Multicentre Clinical Study of Dynamic Monitoring of Plasma ctDNA Methylation Markers to Predict Recurrence of Colorectal Cancer After Complete Resection of Peritoneal MetastasesRecruitingNCT06903325
• MRD-Guided Surveillance in Resectable Stage IV Metastatic Colorectal Cancer (SURVEILLANCE-II)Not yet recruitingNCT06879886
• Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal CancerRecruitingNCT06856187Phase 2
• Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal CancerRecruitingNCT06763029Phase 2
• A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)RecruitingNCT06749015
• SHR-1701 Combined with SHR2554 and BP102 for MCRCNot yet recruitingNCT06679673Phase 2
• To Explore the Effect of Huaier Granule on the Negative Conversion Rate After the CEA Level Increases Again After Colorectal Cancer SurgeryNot yet recruitingNCT06665334Phase 4
• Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal CancerNot yet recruitingNCT06593548Phase 2
• Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal CancerRecruitingNCT06525428Phase 2
• Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal CancerRecruitingNCT06521866Phase 2
• A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With AdebrelimabNot yet recruitingNCT06513221Phase 2
• Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNARecruitingNCT06440902Phase 2
• Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal CancerNot yet recruitingNCT06423937Phase 2
• The Impact of Colorectal Cancer Screening on Surgical OutcomesNot yet recruitingNCT06416501
• Everolimus Combined With PD-1 in Advanced Colorectal Cancer PatientsNot yet recruitingNCT06301386Phase 2
• Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal CancerRecruitingNCT06218810Phase 2
• DEBIRI Combined With Chemotherapy and Bevacizumab in the Treatment of Unresectable Colorectal Cancer Liver MetastasesNot yet recruitingNCT06177288Not applicable
• Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine MonotherapyRecruitingNCT06090994Phase 4
• Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRCRecruitingNCT06010888Phase 2
• Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRCRecruitingNCT05970705Phase 2
• Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal CancerRecruitingNCT05963490Phase 2
• A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 StudyRecruitingNCT05954429Phase 2
• Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal CancerRecruitingNCT05954078Phase 3
• Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-sidednessNot yet recruitingNCT05881746Not applicable
• Postoperative Effects of Different Enterostomy ApproachesRecruitingNCT05853094Not applicable
• Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer PatientsRecruitingNCT05771181Phase 2
• Predictive Value of ctDNA for NED Status in mCRC and Its Utility in Guiding Therapeutic InterventionRecruitingNCT05635630Not applicable
• The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal CancerNot yet recruitingNCT05634590Phase 2
• The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal CancerRecruitingNCT05555901Phase 2
• Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line ChemotherapyNot yet recruitingNCT05451719Phase 2
• A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal MetastasisNot yet recruitingNCT05359393Phase 2
• Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver MetastasisNot yet recruitingNCT05354674
• Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRCRecruitingNCT05229003Phase 2
• Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal CancerRecruitingNCT05086614Phase 3
• CTC vs Radiography as the Evidence of Recurrence in Colorectal Cancer PatientsNot yet recruitingNCT04917289Phase 3
• Treatment Response Prediction System of mCRC Patients Based on CTCNot yet recruitingNCT04917276
• Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical StudyNot yet recruitingNCT04831528
• mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited MetastasesRecruitingNCT04781270Phase 3
• Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver MetastasesRecruitingNCT04687631Phase 3
• Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal CancerRecruitingNCT04516681Phase 3
• Dynamic Monitoring of ctDNA Methylation to Predict Relapse in Colorectal Cancer After Radical Resection (POSTCA)RecruitingNCT03737539
• Comparing 18F-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal MetastasisActive, not recruitingNCT07079462Phase 2
• Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal CancerWithdrawnNCT06221423
• Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world StudyCompletedNCT06202417
• Distinct Metastatic Phenotypes Between Early-onset and Late-onset Colorectal CancerCompletedNCT06040021
• Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal CancerActive, not recruitingNCT05969899Phase 2
• Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis PatientStatus unknownNCT05873972Not applicable
• The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.Status unknownNCT05732129Phase 2
• Evaluation of a Model for the Early Diagnosis of Colorectal Cancer by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNA to the Community Colorectal Cancer Screening ProgramStatus unknownNCT05638243
• VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal CancerStatus unknownNCT05540951Phase 3
• Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard TherapyActive, not recruitingNCT05435313Phase 2
• Effect of FMD on Colorectal Cancer PatientsActive, not recruitingNCT05384444Not applicable
• Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal CancerStatus unknownNCT05193292Phase 2
• Evaluation of Circulating Tumor DNA Guided Surveillance Strategy of Stage III Colorectal Cancer: an Open, Prospective, Randomized Controlled Cohort StudyStatus unknownNCT05161585Not applicable
• A Cohort of Molecular Characteristics and Prognosis of Colorectal CancerStatus unknownNCT05086601
• The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)Status unknownNCT04948034Phase 2
• c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRIStatus unknownNCT04833036Phase 2
• Raltitrexed in HIPECCompletedNCT04761185Phase 1
• Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal CancerStatus unknownNCT04582981Phase 2
• The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal CancerStatus unknownNCT04535024Phase 2
• Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella TheoryStatus unknownNCT04525807
• Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver MetastasesStatus unknownNCT04525326Phase 3
• The Prediction Model of Avastin Plus Chemotherapy in Unresectable Ras Mutant CRLM PatientsStatus unknownNCT04525313
• Cetuximab Re-challenge for Colorectal Cancer Liver MetastasisStatus unknownNCT04509635Phase 3
• A Study of Radiotherapy Combined With Raltitrexed and Irinotecan in Metastatic or Locally Recurrent Colorectal CancerStatus unknownNCT04499586Phase 2
• Effects of Fasting Strategies on Postoperative Recovery and Long-term Prognosis in Patients With Colorectal CancerStatus unknownNCT04345978Not applicable
• Next-generation Sequencing of Colorectal Cancer Somatic Cells to Guide Genetic Susceptibility Gene Mutations Screening.Status unknownNCT04280666
• Use of Plasma ctDNA Methylation Haplotypes in Detecting Local Residual or Lymph Node MetastasisStatus unknownNCT03868215
• Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With ThrombocytopeniaStatus unknownNCT03823079Phase 2
• Application of Radiomics in Precise Preoperative Diagnosis and Prognsis Evaluation of Colorectal Cancer.Status unknownNCT03787667
• The Implication of Plasma ctDNA Methylation Haplotypes in Detecting Colorectal Cancer and AdenomasCompletedNCT03737591
• CRT Versus Surgery for Retroperitoneal or Paraaortic Lymph Node Recurrence of CRCStatus unknownNCT03725254Phase 2
• A Model for Predicting the Efficacy of Conversion Therapy for Patients With Colorectal Cancer Liver Metastases by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNAStatus unknownNCT03679039
• A Multi-center Trial to Establish a Model for the Early Diagnosis of Colorectal Cancer by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNAStatus unknownNCT03676075
• A Model for the Early Diagnosis of Colorectal Cancer by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNAStatus unknownNCT03599947
• Potential Predictive Biomarkers in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal CancerCompletedNCT03532711
• Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal CancerCompletedNCT03485027Phase 2
• Apatinib in the Treatment of Metastatic Colorectal CancerStatus unknownNCT03403452Phase 2
• Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLMStatus unknownNCT03127072Phase 4
• The Value of Diffusion-weighted Imaging in Evaluating the Early Efficacy of Liver Metastasis in Colorectal CancerStatus unknownNCT03088163Not applicable
• Transanal Tube Drainage in Endoscopic Submucosal Dissection of the Colorectal TumorStatus unknownNCT02973490Not applicable